Latest Headlines

  1. CS Analytical Expands USP 1207 Container Closure Integrity Testing Programs For IV Bag Systems 9/21/2023

    CS Analytical Laboratory, the world's only FDA regulated contract laboratory exclusively dedicated to providing regulatory solutions and qualification testing services specifically for drug product and medical device container systems is excited to announce that it had expanded its capabilities to test the ever-challenging IV Bag Container System in accordance with the key concepts of USP 1207 Container Closure Integrity Testing (CCIT) requirements.

  2. Metadeq Diagnostics Announces Three HeparDx™ Posters Will Be Presented At EASL SLD Summit 2023 9/20/2023

    Metadeq Diagnostics, Inc., a private medical diagnostic company developing tests for NASH/MASH and liver fibrosis, today announced the presentation of three posters at the EASL SLD Summit 2023 in Prague, Czech Republic.

  3. Tasso Receives CE Mark Certification For Tasso+, Latest Generation Whole Blood Collection Lancet Device 9/19/2023

    Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced it received CE Mark certification for its Tasso+ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples.

  4. bioAffinity Technologies Acquires Laboratory Assets Of Precision Pathology Services 9/19/2023

    bioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.

  5. Pillar Biosciences Launches oncoReveal™ Core LBx, An NGS Kit To Enable Localized Liquid Biopsy Testing 9/19/2023

    Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal ™ Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.

  6. TissueCypher Barrett’s Esophagus Test Outperformed Standard Of Care In Risk-Stratifying Patients With Barrett’s Esophagus 9/14/2023

    Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced the publication of data demonstrating that the TissueCypher Barrett’s Esophagus test outperformed standard of care pathology review in predicting malignant progression to HGD and EAC in BE patients with an initial diagnosis of LGD.

  7. Vial Announces Collaborative Alliance With MLM Medical Labs 9/14/2023

    Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with MLM Medical Labs ("MLM"), an international central and specialty laboratory with locations in Europe and North America.

  8. Lego-Like Gene Editing Tool Lets Researchers Improve Cancer Immunotherapy 9/14/2023

    In recent years, scientists have used gene modification technologies to reprogram immune cells into therapeutics that can attack cancers.

  9. Clinical Whole Genome Sequencing Test Developed At The Jackson Laboratory 9/14/2023

    Until quite recently, it was extremely difficult to detect the variants underlying many genetic disorders. In the absence of a defined cause, clinicians have little to guide treatment for those left without a genetic diagnosis, forcing patients and families to embark on a diagnostic odyssey with no guarantee of finding answers.

  10. Us2.ai Partners With Leading Academic Medical Center To Collaborate On AI-Enabled Echocardiography Software 9/13/2023

    Us2.ai, a Singapore-based MedTech firm, has partnered with Duke University to co-develop and commercialize AI tools for echocardiography, to enable earlier detection, improved diagnosis and more efficient management of heart disease.